An Evidence-Based Roadmap for Cancer Control in the United States (2026–2035)

By Editorial Team -

Abstract

Importance: Cancer remains the second leading cause of death in the United States, despite substantial advances in prevention, screening, and treatment.
Objective: To synthesize current evidence and outline a realistic, data-driven roadmap for reducing cancer mortality and improving outcomes between 2026 and 2035.
Evidence Review: Evidence was drawn from reports by the American Cancer Society, National Cancer Institute, and Centers for Disease Control and Prevention, as well as peer-reviewed studies in The New England Journal of Medicine, JAMA, and the Journal of the National Cancer Institute.
Findings: The most impactful interventions include tobacco control, vaccination, evidence-based screening, precision oncology, and standardized care delivery. Prevention and early detection account for a substantial proportion of mortality reduction.
Conclusions and Relevance: A comprehensive cancer strategy emphasizing prevention, early detection, and equitable delivery of evidence-based care is likely to yield the greatest improvements in population-level outcomes.



Introduction

Cancer continues to impose a major public health burden in the United States. According to the American Cancer Society, approximately 1.9 million new cancer cases and more than 600,000 deaths are expected annually.¹ Over the past three decades, cancer mortality has declined by approximately 33%, reflecting advances in prevention, screening, and treatment.¹

Credit: Statista

Despite this progress, challenges persist. Many cancers are still diagnosed at advanced stages, disparities in outcomes remain, and costs continue to rise.² These realities underscore the need for a coordinated, evidence-based roadmap for cancer control.

Methods

This narrative review synthesizes evidence from:

  • National agencies: National Cancer Institute, Centers for Disease Control and Prevention

  • Clinical guidelines: U.S. Preventive Services Task Force

  • Peer-reviewed literature (NEJM, JAMA, JNCI)

Priority was given to:

  • Randomized controlled trials

  • Large observational studies

  • Government and consensus reports

Results

1. Prevention

Tobacco use remains the leading preventable cause of cancer. The National Cancer Institute estimates that smoking accounts for approximately 30% of cancer deaths in the United States.³

Obesity is another major risk factor, linked to at least 13 cancer types.⁶

2. Early Detection

Screening is one of the most effective tools for reducing cancer mortality. The U.S. Preventive Services Task Force recommends screening for breast, colorectal, cervical, and lung cancers in appropriate populations.⁷

The National Lung Screening Trial demonstrated a 20% reduction in lung cancer mortality with low-dose computed tomography screening among high-risk individuals.⁸

Emerging technologies such as multi-cancer early detection (MCED) tests show promise but are not yet standard of care.⁹

3. Precision Oncology

Advances in molecular profiling have enabled targeted therapies for specific genetic alterations. These approaches improve outcomes in selected patient populations and are incorporated into clinical practice guidelines from the National Comprehensive Cancer Network.

4. Immunotherapy

Immune checkpoint inhibitors, such as Pembrolizumab, have transformed the treatment of several cancers. Clinical trials have demonstrated durable responses in malignancies including melanoma and non–small cell lung cancer.¹⁰

However, response rates vary, and treatment-related toxic effects remain a concern.

5. Standardization of Care

Adherence to evidence-based guidelines is associated with improved outcomes. Variability in care delivery remains a significant barrier to optimal cancer control.

6. Clinical Trials and Research Infrastructure

Fewer than 5% of adult cancer patients participate in clinical trials, limiting the generalizability of findings and slowing progress.¹¹ Expanding access to trials is a key priority.

7. Cost and Sustainability

Cancer care costs are projected to exceed $245 billion annually by 2030.² Strategies such as value-based pricing and increased use of biosimilars may help mitigate cost growth.

Discussion

This review highlights that the greatest gains in cancer outcomes are likely to come from:

  • Prevention (tobacco control, vaccination, obesity reduction)

  • Early detection (screening and emerging technologies)

  • Evidence-based, standardized treatment

While novel therapies such as immunotherapy and precision medicine have improved outcomes for some patients, their population-level impact is limited without broader implementation of preventive and early detection strategies.

Importantly, there is currently insufficient high-quality evidence to support the use of alternative therapies as primary cancer treatments.¹²

Limitations

This review is narrative in nature and does not include a formal systematic review or meta-analysis. Some emerging technologies, such as MCED tests, are still under investigation.

Conclusions

An effective cancer control strategy for the United States must prioritize:

  1. Prevention

  2. Early detection

  3. Equitable access to high-quality care

  4. Cost sustainability

A comprehensive, evidence-based approach has the potential to further reduce cancer mortality and improve outcomes over the next decade.

References

  1. American Cancer Society. Cancer Facts & Figures 2024.
    https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2024-cancer-facts-figures.html

  2. Mariotto AB, et al. Projections of the cost of cancer care in the United States. JNCI.
    https://pubmed.ncbi.nlm.nih.gov/31850803/

  3. National Cancer Institute. Tobacco and Cancer.
    https://www.cancer.gov/about-cancer/causes-prevention/risk/tobacco

  4. Centers for Disease Control and Prevention. HPV and Cancer.
    https://www.cdc.gov/hpv/parents/cancer.html

  5. Falcaro M, et al. The effects of HPV vaccination on cervical cancer. Lancet.
    https://pubmed.ncbi.nlm.nih.gov/33271093/

  6. National Cancer Institute. Obesity and Cancer.
    https://www.cancer.gov/about-cancer/causes-prevention/risk/obesity

  7. U.S. Preventive Services Task Force. Screening Recommendations.
    https://www.uspreventiveservicestaskforce.org

  8. National Lung Screening Trial Research Team. NEJM.
    https://www.nejm.org/doi/full/10.1056/NEJMoa1102873

  9. National Cancer Institute. Multi-Cancer Detection Tests.
    https://www.cancer.gov/about-cancer/screening/multi-cancer-detection

  10. Robert C, et al. Pembrolizumab in melanoma. NEJM.
    https://www.nejm.org/doi/full/10.1056/NEJMoa1606774

  11. National Cancer Institute. Clinical Trials Participation.
    https://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials

  12. National Cancer Institute. Complementary and Alternative Medicine.
    https://www.cancer.gov/about-cancer/treatment/cam

Comments

Post a Comment

Labels

Show more

Archive

Show more

Popular posts from this blog

Fenbendazole, Ivermectin and Mebendazole Cancer Success Stories: 597 Case Reports Compilation (March 2026 Edition)

By Editorial Team -
Image
Table of Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Breast Cancer Success Stories  (77 cases) Brain Cancer (including Glioblastoma) (119 cases) Bile Duct Cancer (Cholangiocarcinoma)  (4 cases) Bladder Cancer Success Stories  (including kidney cancer) (29 cases) Cervical Cancer  (6 cases) Colorectal Cancer  (including Appendix cancer) (52 cases) Esophageal and Stomach cancer (21 cases) Endometrial Cancer (9 cases) Gastric (Stomach) cancer (see  Esophageal and Stomach Cancer ) (21 cases) Head and Neck Cancer (15 cases) Kidney Cancer Case Series  (including urinary (urothelial) bladder cancer) (27 cases) Liver Cancer (HepatoCellular Cancer)  (3 cases) Lung Cancer (43 cases) Leukemia (9 cases) Lymphoma (23 cases) Melanoma (refer to Skin Cancer ) ...
Read more

Ivermectin and Fenbendazole: Treating Turbo Cancer - Dr William Makis

By Editorial Team -
Image
Ivermectin Resources I have seen tremendous demand for some sort of initial guidance “WHERE TO START” with High Dose Ivermectin for CANCER. Editor's Note: Dr Makis proposes four distinct cancer protocols for using Ivermectin in cancer treatment, specifically for patients who have developed turbo cancer or aggressive cancers. These protocols, referred to as the “Dr. Makis Ivermectin Cancer Protocols,” are categorized based on dosage and the severity of the cancer. Updated version I have an article and a video that go into depth: June 10, 2024 - "15 minutes with Dr.Makis" - Episode 018: High Dose Ivermectin and Cancer .  2025 - 2026 studies on ivermectin for cancer Clinical Yuan Yuan et al (Cedars-Sinai Medical Center) - A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer (ASCO 2025) Yuwen et al -  A Review of Ivermectin Use in Cancer Patients: Is it Time to Repurpose t...
Read more

Fenbendazole Joe Tippens Protocol: A Step-by-Step Guide (2026)

By Editorial Team -
Image
If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories . We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discovered, through trial and error, a product in their canine product line, fenbendazole, that was batting 1.000 in killing these different cancers in the mice. The scientist was later diagnosed wit...
Read more

Ivermectin, Fenbendazole and Mebendazole Protocol in Cancer: Peer-Reviewed Protocol in Cancer

By Editorial Team -
Image
We are pleased to announce that the first-of-its-kind protocol utilizing Ivermectin, Mebendazole, and Fenbendazole for cancer treatment has been peer-reviewed and officially published on September 19, 2024. Spearheaded by leading researchers like Dr. Ilyes Baghli, Dr. Pierrick Martinez, and the FLCCC’s Dr. Paul Marik, this groundbreaking protocol harnesses the untapped power of Ivermectin, Mebendazole, and Fenbendazole, known for their effectiveness against parasites. Now, these drugs are showing potential to battle cancer, marking the dawn of a new treatment evolution. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondri...
Read more

Ivermectin Tested against 28 types of Cancer: Most Sensitive vs Least Sensitive

By Editorial Team -
Image
A research group from Mexico investigated Ivermectin in Cancer. This is the first study that has tested as many as 28 Cancer types with Ivermectin.  Paper: 2020 (Juarez et al) - Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug.  Ivermectin was tested at 2mg/kg/day which translates to roughly 5uM in vitro concentration. The most sensitive cancer cell lines were: 1. Ovarian 2. Breast 3. Glioblastoma 4. Lung Cancer 5. Colon Cancer 6. Uterine SCC 7. hepatocellular 8. breast TNBC 9. Pancreatic 10. Endometrial. Least sensitive were: 1. osteosarcoma 2. gastric 3. melanoma  Although lymphoma and leukemia cell lines appear to be more resistant to Ivermectin, Ivermectin has a significant impact on those cells' ability to form colonies. So yes, Ivermectin is useful against BOTH lymphomas and leukemias.  Ivermectin also goes after CANCER STEM CELLS, which tend to be resistant to chemotherapy: ...
Read more

Dr William Makis Ivermectin Protocol 2026 – Complete Guide + Patient Outcomes

By Editorial Team -
Image
Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) runs the world's largest high-dose ivermectin cancer clientele in 2025 – he has guided thousands of patients globally with remarkable results in turbo cancers and conventional failures. This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels). Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medical monitoring, as misuse can lead to serious side effects and drug interactions. ...
Read more

Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types (2026)

By Editorial Team -
Image
Introduction This article discusses dosage considerations and key factors regarding the use of ivermectin in cancer treatment. Commonly available information about ivermectin dosages is often inaccurate when applied to potential cancer-related uses.  Many sources cite standard dosages recommended by Merck for treating parasitic infections, rather than dosages studied specifically in the context of cancer research. The anti-parasitic dosage is not as effective for people looking for a dosage against cancer. Dosage will need to be adjusted according to the  current weight, the type of Cancer, the stage and grade of the Cancer and the health of the liver. Ivermectin dosage should also be based on ivermectin cancer studies. Multiple factors are considered including studies including ivermectin for cancer, anecdotal studies and case series, the aggressiveness of the cancer type and the cancer stage. It also takes into account the types of medications the person uses. For example, i...
Read more

Ivermectin Dosage Guide for Humans (2025)

By Editorial Team -
Image
In this Article: Overview of Ivermectin Dosage | Ivermectin Dosage for Adults | Ivermectin Dosage for Children | Ivermectin dosage restrictions | How to take ivermectin | Ivermectin dosage FAQs The prescribed dosage for ivermectin oral tablets depends on the type of parasitic infection you have and your body weight. Ivermectin is typically taken as a single dose. Repeat doses may be needed in some cases. Specifically, ivermectin oral tablet is approved by the Food and Drug Administration (FDA) to treat the following conditions in adults and certain children: a parasitic infection in the intestinal tract called strongyloidiasis a parasitic infection of the eyes and skin called onchocerciasis  (River Blindness) Ivermectin oral tablet is a generic medication and belongs to a drug class called antiparasitic medications. It is also available in a brand-name version called Stromectol. This article describes the dosages of ivermectin oral tablets, as well as the medication’s streng...
Read more

DMSO 101: Benefits, Uses, Dosage and Side Effects (2026)

By Editorial Team -
Image
In 2022, Erica Eyres, a vigorous fifty-six-year-old aerobics instructor who had struggled to breathe, was given “absolutely devastating” news: She might need a lung transplant. She had never smoked, ran cross-country track in high school, and was a personal trainer for years, but, by 2024, a transplant assessment was arranged. “I decided that I will make that decision,” she said, “only if it’s the last resort, and I’m on my deathbed.” A few months before her consultation, however, Eyres, then fifty-eight, made an appointment with a new primary care doctor for routine prescription refills. She was about to be introduced, literally and figuratively, to a new kind of medicine. It would change everything. DMSO Online Buying Guide (Paid Link) Buy on Amazon Disclosure: OneDayMD.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program that enables sites to earn advertising fees by advertising and linking to Amazon.com, but this is at NO extra cost t...
Read more

Best Fenbendazole Dosage for Humans: Safety, Side Effects and Efficacy Examined (2026)

By Editorial Team -
Image
Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some fenbendazole advanced cancer success stories  (more than 500 case reports). Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different m...
Read more